Table 3.
Genotype and response to chemotherapy among NSCLC patients (n = 113)
| Genotype | Cases | Response to chemotherapy | OR (95% CI) | P value | Adjusted OR (95% CI) | Adjusted P value | |
|---|---|---|---|---|---|---|---|
| CR + PR (%) n = 30 | SD + PD (%) n = 83 | ||||||
| MRP2 (C-24T) | |||||||
| C/C | 66 | 11 (36.7) | 55 (66.3) | 1 | 0.015 | 4.069 (1.518–10.910) | 0.005 |
| C/T | 43 | 16 (53.3) | 27 (32.5) | 2.959 (1.211–7.246) | 0.023 | 10.514 (0.842–131.319) | 0.068 |
| T/T | 4 | 3 (10.0) | 1 (1.2) | 14.925 (1.425–166.667) | 0.005 | 4.493 (1.728–11.682) | 0.002 |
| C/T+T/T | 47 | 19 (63.3) | 28 (33.7) | 3.390 (1.420–8.130) | |||
| MRP2 (Val417Ile) | |||||||
| G/G | 84 | 20 (66.7) | 64 (77.1) | 1 | |||
| G/A | 26 | 9 (30.0) | 17 (20.5) | 1.695 (0.654–4.386) | 0.274 | 1.910 (0.697–5.229) | 0.208 |
| A/A | 3 | 1 (3.3) | 2 (2.4) | 1.600 (0.138–18.519) | 0.568 | 1.616 (0.115–22.779) | 0.722 |
| G/A+A/A | 29 | 10 (33.3) | 19 (22.9) | 1.684 (0.674–4.202) | 0.262 | 1.879 (0.710–4.968) | 0.204 |
| MRP2 (Ile1324Ile) | |||||||
| C/C | 74 | 20 (66.7) | 54 (65.1) | 1 | |||
| C/T | 33 | 8 (26.7) | 25 (30.1) | 0.864 (0.335–2.227) | 0.762 | 1.066 (0.385–2.951) | 0.901 |
| T/T | 6 | 2 (6.7) | 4 (4.8) | 1.350 (0.229–7.937) | 0.665 | 1.508 (0.210–10.830) | 0.683 |
| C/T+T/T | 39 | 10 (33.3) | 29 (34.9) | 0.931 (0.385–2.252) | 0.874 | 1.133 (0.441–2.911) | 0.796 |
| GSTP1 (Ile105Val) | |||||||
| A/A | 71 | 13 (43.3) | 58 (69.9) | 1 | |||
| A/G | 38 | 15 (50.0) | 23 (27.7) | 2.907 (1.200–7.042) | 0.016 | 2.788 (1.106–7.029) | 0.030 |
| G/G | 4 | 2 (6.7) | 2 (2.4) | 4.464 (0.574–34.483) | 0.176 | 4.083 (0.457–36.463) | 0.208 |
| A/G+G/G | 42 | 17 (56.7) | 25 (30.1) | 3.030 (1.282–7.194) | 0.010 | 2.881 (1.167–7.113) | 0.022 |
Adjusted OR (95% CI): OR (95% CI) after adjusting for patient gender, age at diagnosis, tumor histology, disease stage, and chemotherapy regimens